NewHavenBIZ

n e w h a v e n b i z . c o m | N o v e m b e r 2 0 2 1 | n e w h a v e n B I Z 9 $ 9,370 * health plan refund? Now, that's refreshing. It's possible with an Oxford Level Funded health plan — built to help your business get back to business faster. Level funded plans are based only on your plan participants, so if their medical claims are lower than expected, your health plan may get a surplus refund* at year-end. For details and a quote, contact your broker or Oxford representative * Yep, that's a real number. Among the 36% of UnitedHealthcare's level funded business customers nationwide who received a refund, the average refund was $9,370. UnitedHealthcare internal reconciliation analysis, April 1, 2020 through March 31, 2021. Please consult a tax and/or legal advisor to determine if, by receiving this refund, there are any restrictions or obligations. Surplus refund available only where allowed by state law. Administrative services provided by Oxford Health Plans LLC. Stop-loss insurance is underwritten by All Savers Insurance Company in CT, UnitedHealthcare Life Insurance Company in NJ, and UnitedHealthcare Insurance Company of New York in NY. B2B EI21987012.0-OXF 9/21 © 2021 Oxford Health Plans LLC. All Rights Reserved. 21-813504-M measure how highly active they are. And because we are able to measure these superhero cells, we are really able to reveal a lot of new biology. ere are about 40,000 systems right now in the world that can measure the surface of the cell and understand how those cells play out. But our ability to functionally define the cell for these superhero characteris- tics is unique. What we are seeing is, it is really a high need, as we emerge into pharma and academic medical centers. Can your technology help combat a range of diseases? Indeed. What we have seen is that our tech, leveraging these powerful sets of cells, has been used against various cancers, solid tumors, blood cancers, but also, more recently, we have been able to identify inflammatory reactions. For example, in COVID-19. We have seen some precursors of transplant re- jection, that is another area, so it is an interesting application. We are able to understand sources of the immune sys- tem, we call them supervillain respons- es, inflammatory responses against the self, by finding these hypercharged immune cells. Is the company involved in the de- velopment of vaccines, such as for COVID-19? We had some pretty important work in COVID-19 last year, it was pub- lished in the journal, Cell. We were able to really detect early sources of inflammation, which is pretty much the worst part of getting COVID. You have this bad inflam- mation that sends people to the ICU. Information like that becomes very important. We are doing that type of work, and we hope to be a part of contributing to that understanding of how to pow- er and leverage our immune system against cancers, infectious diseases and inflammatory diseases in the future. What are your annual revenues? Revenue for the fiscal years ended December 31, 2019 and 2020, was $7.5 million and $10.4 million, respectively, and revenue for the six months ended June 30, 2020 and 2021, was $3.7 million and $7.5 million, respectively. How is the company using the money it raised in the past year? We raised $135 million back in Janu- ary and we raised another $125 million in the IPO. A lot of the expansion has gone into hiring new people. ey are going into our commercial team, which is incredibly important as we expand worldwide, not only domestically, but all the international regions, including Europe and Asia/Pacific. We will really continue to scale up operations. We grew at 103% reve- nue-wise through the first half of the year. What you need to do is manu- facture, operate and deliver to that de- mand. We have expanded our footprint in Connecticut. We believe so much in the innovation in our industry, and we are continuing to hire people to innovate. We will real- ly invest in research and development, come out with great products, and continue to solve critical problems. Where do you see the company in five years? 10 years? Right now, the main source of our business is we sell our systems and we generate this amazing single-cell pro- teomic [the study of proteins and their functions] data. We have multiple other product lines that work on our systems coming out, and those include looking more around the blood, for proteins. We have prod- ucts that look at the DNA, so doing sequencing. We have a real chance here to highly influence how people develop and then deliver these really complex therapeutics. It has been an incredible journey what we have done for the past seven or so years here in Connecticut. We are excited for the next 10 years. ere is so much new biology that is out there. e people we have are working hard and will continue to work hard to deliver on high expectations for us in the coming years. n IsoPlexis' IsoLight platform.

• Cover